Retatrutide, a experimental dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) target, is demonstrating promising data in early clinical trials . Current examination https://bookmarkmargin.com/story21354128/retatrutide-emerging-research-and-potential-medical-roles